Elsevier / Gold Standard Announces New Drug Class Overviews for Clinical Pharmacology

TAMPA, Florida, August 22, 2012 /PRNewswire/ --

Drug Class Overviews revamped to address the changing needs of health care professionals

Leading drug information provider Elsevier / Gold Standard announced today its new Drug Class Overviews, making Clinical Pharmacology more valuable at the point of care.

Clinical Pharmacology Drug Class Overviews are now even more powerful for evaluating formulary decisions and therapeutic drug substitutions.  Elsevier / Gold Standard has improved the speed and usability of the content through bulleted summaries and tables, highlighting a variety of critical areas in drug-interaction information.

"The new Drug Class Overviews represent a significant evolution in our content development that was stimulated and driven by input from our clients," said Elsevier / Gold Standard President Marianne Messer.  "This advancement also represents the way in which our users wish to utilize our vast amount of drug information that is updated in real-time."

The new Drug Class Overviews includes:

• A summary in simple bullet format
• Pharmacology/Mechanism of Action with key pharmacology and pharmacokinetics and tables to highlight differences
• Therapeutic Use, highlighting place in therapy, alternatives within a class, and key clinical differences with labeled, off-label, and not recommended indications
• Comparative Efficacy, highlighting randomized control trials for one or more indications
• Adverse Reactions/Toxicities summarizes serious adverse events and toxicities
• Drug Interactions, helping clinicians determine which drugs to use
• Safety Issues, highlights all contraindications and indicates BBW's, REMS, or MedGuides.

"Clinical Pharmacology has been named by independent research studies as the most complete and dependable drug reference solution on the market today.  It is trusted by thousands of hospitals, 35,000 retail pharmacies, health plans, pharmacy benefit managers (PBMs), pharmaceutical manufacturers, and academic institutions," Messer said.  "We are pleased to continue developing our solutions and meeting the needs of our users."

For more information about Clinical Pharmacology and the new Drug Class Overviews, please visit http://www.goldstandard.com.

About Elsevier / Gold Standard

Based in Tampa, FL, Elsevier / Gold Standard uses innovative technologies to provide a complete suite of drug information and decision support solutions. With a tenacious commitment to product quality, Elsevier / Gold Standard solutions empower healthcare organizations, professionals and consumers to meet the most pressing healthcare challenges, improve patient safety and ensure optimal outcomes. To learn more about Elsevier / Gold Standard, visit http://www.goldstandard.com.

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Chris Capot
Director, Corporate Relations, Elsevier
+1-212-633-3164
c.capot@elsevier.com